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Satellite DNAAn infection and treatment protocol is used to vaccinate cattle against Theileria parva infection. Due to
incomplete cross-protection between different parasite isolates, a mixture of three isolates, termed the
Muguga cocktail, is used for vaccination. While vaccination of cattle in some regions provides high levels
of protection, some animals are not protected against challenge with buffalo-derived T. parva. Knowledge
of the genetic composition of the Muguga cocktail vaccine is required to understand how vaccination is
able to protect against field challenge and to identify the potential limitations of the vaccine. The aim of
the current study was to determine the extent of genetic and antigenic diversity within the parasite iso-
lates that constitute the Muguga cocktail. High throughput multi-locus sequencing of antigen-encoding
loci was performed in parallel with typing using a panel of micro- and mini-satellite loci. The former
focused on genes encoding CD8+ T cell antigens, believed to be relevant to protective immunity. The
results demonstrate that each of the three component stocks of the cocktail contains limited parasite
genotypic diversity, with single alleles detected at many gene/satellite loci and, moreover, that two of
the components show a very high level of similarity. Thus, the vaccine incorporates very little of the
genetic and antigenic diversity observed in field populations of T. parva. The presence of alleles at low
frequency (<10%) within vaccine component populations also points to the possibility of variability in
the content of vaccine doses and the potential for loss of allelic diversity during tick passage. The results
demonstrate that there is scope to modify the content of the vaccine in order to enhance its diversity and
thus its potential for providing broad protection. The ability to accurately quantify genetic diversity in
vaccine component stocks will facilitate improved quality control procedures designed to ensure the
long-term efficacy of the vaccine.
 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Live vaccines are available for a number of economically impor-
tant diseases of farm animals caused by protozoal parasites includ-
ing Babesia bovis, Theileria parva and Theileria annulata in cattle,
Toxoplasma gondii in sheep and Eimeria spp. in poultry (reviewed
by McAllister, 2014). Extensive efforts to develop alternative, more
easily manufactured, vaccines based on use of defined antigens,
have met with limited success. Hence, vaccination against these
diseases will continue to rely on the available live vaccines forthe foreseeable future. Similar slow progress in developing subunit
vaccines for malaria has also prompted recent efforts to develop a
live vaccine using Plasmodium sporozoites harvested from infected
mosquitos (Hoffman, 2012; Hodgson et al., 2015). Antigenic
heterogeneity is an important feature of some of these protozoa,
notably T. parva (Morrison et al., 2015) and Eimeria tenella (Blake
et al., 2015), requiring the inclusion of more than one parasite
genotype in the vaccines.
Theileria parva, transmitted by Rhipicephalus appendiculatus
ticks, causes an acute lymphoproliferative disease of cattle, which
is a major constraint to livestock production throughout a large
part of east and southern Africa. Due to the fatal nature of the dis-
ease in cattle and shortcomings of therapeutic drugs and measures
to control tick infestation, vaccination offers the most sustainable
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ing infection of cattle with T. parva sporozoites and simultaneous
treatment with long-acting tetracycline, referred to as the infection
and treatment method, was developed over 40 years ago (Radley
et al., 1975). The initial work demonstrated that immunisation
with one parasite isolate resulted in solid, long-lasting immunity
against challenge with the same isolate; however, a proportion of
animals remained susceptible to challenge with other isolates
(Radley et al., 1975). Following a series of immunisation and chal-
lenge experiments, a combination of three parasite isolates was
identified, which generated immunity against experimental chal-
lenge with a range of T. parva isolates of cattle origin (Radley
et al., 1975) and against field challenge (Radley, 1978). This vac-
cine, commonly referred to as the Muguga cocktail, contains the
Muguga, Kiambu 5 and Serengeti isolates of T. parva. The former
two isolates were derived by feeding ticks on infected cattle,
whereas the Serengeti component was originally isolated by feed-
ing ticks on an African buffalo after which it was adapted to cattle
through tick passage (Young and Purnell, 1973). Until recently, use
of the Muguga cocktail vaccine in the field has been limited, largely
due to the complex process involved in production and quality
control of sporozoites and the requirement for a cold chain to store
and distribute the vaccine. However, a recent initiative to establish
a centre for vaccine production (http://www.galvmed.org/en/live-
stock-and-diseases/livestock-diseases/east-co) and systems to
facilitate its distribution have led to increased field uptake.
Despite evidence of efficacy of the Muguga cocktail vaccine in
some field settings (Di Giulio et al., 2008; Martins et al., 2010), fail-
ure to protect a proportion of immunised animals has been
observed following exposure to tick challenge in a paddock exper-
imentally seeded with buffalo-derived T. parva (Radley et al., 1979).
Moreover, in more recent studies, vaccinated animals exposed to
natural field challenge in sites grazed by buffalo were found to be
susceptible to challenge (Bishop et al., 2015; Sitt et al., 2015). As
indicated previously (Bishop et al., 2001), more detailed knowledge
of the genetic composition of the Muguga cocktail vaccine is
required, not only to understand how the vaccine content relates
to its ability to protect against field challenge with T. parva but also
to facilitate quality control during vaccine production. Although the
protective capacity of the vaccine is believed to reflect genotypic
diversity of the constituent parasites at antigen-encoding loci,
information on the genetic composition of the parasite populations
within each of the vaccine components is limited. Allelic polymor-
phism of three genes encoding antigens recognised by immune sera
has been documented in the components of the Muguga cocktail
using restriction fragment length polymorphism analysis and/or
monoclonal antibody reactivity (Geysen et al., 1999; Bishop et al.,
2001). More recently, a whole-genome sequencing approach has
been applied to characterising Muguga cocktail component stocks
(Norling et al., 2015). While this confirmed genetic diversity among
the components, intra-component diversity was not detected
beyond the expected error level of the sequencing platform
employed. The most discriminant method for examining intra-
component genetic diversity to date has been the use of micro-
and mini-satellite markers; these have been employed to demon-
strate diversity both between and within the vaccine cocktail com-
ponents (Oura et al., 2004, 2007; Patel et al., 2011).
The short ‘variable number of tandem repeat’ regions detected
by micro- and mini-satellite genotyping are broadly distributed
in eukaryotic genomes (Tautz and Renz, 1984). As they possess a
relatively high rate of mutation, they represent useful markers
for high-resolution molecular fingerprinting of eukaryotic patho-
gens. These loci, for the most part, do not encode proteins involved
in stimulating host immunity and can only be used as a proxy for
assessing antigen diversity if they are closely physically linked to
antigen-encoding loci. Moreover, micro- and mini-satellitegenotyping is not well suited to detecting low abundance geno-
types within mixed parasite populations, since minor alleles can
be difficult to differentiate from PCR artefacts.
Previous studies provided evidence that CD8+ T cell responses
specific for parasitised lymphoblasts are key mediators of immu-
nity generated by infection and treatment vaccination (McKeever
et al., 1994; Taracha et al., 1995a). Recently, a number of T. parva
antigens recognised by CD8+ T cells from immune animals were
identified and several of these antigens have been shown to be
polymorphic in field populations (Pelle et al., 2011). In this study,
high-throughput multi-locus sequencing of antigen-encoding loci
was performed, focusing on genes encoding parasite antigens
believed to be relevant to protective immunity. A panel of micro-
and mini-satellite loci was also utilised in order to gain a broad
understanding of genetic diversity within the Muguga cocktail.2. Materials and methods
2.1. Samples and DNA extraction
Four batches of Muguga cocktail vaccine stabilate (ILRI 0801–
ILRI 0804) and the corresponding reference stabilates (Muguga –
4230; Serengeti – 4229; Kiambu 5 – 4228), prepared previously
as described by Patel et al. (2016), were used in this study. Both
the reference stabilates and the vaccine stabilates had been pre-
pared from ticks infected with the same parent stabilates (Muguga
– 73, Serengeti – 69 and Kiambu 5 – 68). Three batches of infected
ticks, each obtained from cattle infected with one of the compo-
nent stabilates (68, 69 and 73) were used at different times to pre-
pare the reference and vaccine stabilates. The latter were prepared
from a mixture of ticks from the three batches. Following moulting
to adults, ticks from each of the batches were fed on rabbits for
4 days and a sample of the ticks was used to determine the infec-
tion rates in each batch of ticks, based on examination of dissected
salivary glands. The final mixture of the ticks was prepared to
ensure there were equivalent numbers of acini infected with para-
sites from each of the component stabilates. The tick mixture was
homogenised, suspended in 7.5% glycerol and cryopreserved in ali-
quots in liquid nitrogen (Cunningham et al., 1973). The four vac-
cine batches were prepared from a subset of the same batches of
ticks processed 1 week apart. Following preparation of the vaccine
stabilates, the three reference stabilates were prepared separately
from ticks infected with each of the three parasites. These stabi-
lates (4228, 4229 and 4230) are currently being used to produce
future batches of vaccine.
An additional sporozoite stabilate (3014) of the Marikebuni
T. parva stock was also examined. This stock, which has been used
on a more limited scale for vaccination by infection and treatment
(Mutugi et al., 1989), was originally isolated from a field tick col-
lection in the coastal district of Kenya and had undergone three
laboratory passages through ticks (Irvin et al., 1983; Mutugi
et al., 1989). This stock was used as a comparator in order to inves-
tigate how the diversity in a single isolate used for vaccination
compares with that of the trivalent Muguga cocktail.
For DNA extraction, excess tick debris was first removed from
thawed sporozoite stabilates by centrifuging at 100g for 5 min
and the supernatant containing the sporozoites transferred to a
clean Eppendorf tube. The sporozoites were pelleted at 16,000g
before DNA was extracted using the Qiagen DNeasy Blood and
Tissue Kit.2.2. Micro- and mini-satellite DNA typing
PCR amplification was performed using micro- and mini-
satellite markers described by Oura et al. (2003, 2005). Fifteen
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parasite genome were used, namely ms2, MS3, ms7, MS7, MS8,
MS14, MS15, MS19, MS21, MS25, MS27, MS30, MS33, MS39 and
MS40 (genome references provided in Katzer et al., 2010). PCR con-
ditions were similar to those described previously, except that one
primer of each primer pair was labelled at the 50 end with the flu-
orophore FAM (Eurofins Genomics, UK). Allele sizes were deter-
mined using capillary flow electrophoresis and detection of the
fluorophore signal from the labelled primer in each amplicon. This
was done using GenescanTM technology (Applied BioSystems, UK)
with the GSLIZ500 size standards. Only peaks in the range of
100–500 bp were considered for further analysis. The relative
abundance of individual peaks was determined and expressed as
a percentage of the total area under the curve for all peaks of the
appropriate colour in the trace combined. Peaks with an area of
less than 3% of the total area under the curve for all peaks were
excluded. Traces were inspected and alleles were manually ‘called’.
F-statistic values were calculated from the mini- and
microsatellite typing data from the different parasite stocks and
were utilised to carry out principal co-ordinate analysis (PCoA).
The Microsoft plug-in Genalex6 (Peakall and Smouse, 2012) was
used to perform PCoA.
2.3. Theileria parva CD8+ T cell antigens
Ten T. parva genes (Tp1–Tp10) known to encode antigens recog-
nised by immune CD8+ T cells were investigated. Identification of
Tp1 (TP03_0849), Tp2 (TP01_0056), Tp4 (TP03_0210), Tp5
(TP02_0767), Tp7 (TP02_0244) and Tp8 (TP02_0244) antigens
and their T cell epitopes has been reported previously (Graham
et al., 2006, 2008). The same authors also identified a further two
antigens, Tp3 and Tp6, corresponding to T. parva genome IDs
TP01_0868 and TP01_0188, respectively. Tp9 and Tp10 (genome
IDs TP02_0895 and TP04_0772, respectively) were identified
subsequently by two of the current authors (ND MacHugh and SP
Graham) using parasite-specific CD8+ T cells to screen a parasite cDNA
library as described previously (Graham et al., 2006); Tp9 and Tp10
were shown to be presented by the 1⁄02301 and 3⁄00201 class I
major histocompatibility complex (MHC) alleles, respectively,
and a single CD8+ T cell epitope (Tp967–75 – AKFPGMKKS;
Tp10419–427 – NNPELIPVL) was identified in each by screening syn-
thetic peptides as described elsewhere (Graham et al., 2008).
2.3.1. Sanger sequencing
The full-length open reading frame (ORF) of the Tp2 and Tp9
genes, and a segment of the Tp1 gene, located between nucleotides
523 and 954, were sequenced from a series of cloned parasitised
cell lines derived from each of the three constituent Muguga cock-
tail parasite stocks (Patel et al., 2011). The primers and PCR condi-
tions used for amplification of the Tp1 and Tp2 sequences have
been described previously (Pelle et al., 2011). Primers for Tp9 (for-
ward: 50-ATGAATGTTCTAACTACTGG-30; reverse: 50-TTATTGTTTTG
TCCATGGTTTATTACG-30) were designed based on the first 20 and
the last 27 nucleotides of the Tp9 ORF from the Muguga reference
isolate F100 TpM (GenBank accession number XM_760370). A sec-
ond set of primers (forward: 50-ACCCCATCCATTTGACAG-30 and
reverse 50-CCTGGCATTAAGGTACTC-30), designed to amplify a pro-
duct of 369 bp of the genomic sequence of Tp9, with the forward
primer located 78 bp downstream of the start codon, was used to
generate PCR products from the Marikebuni stock (stabilate
3014). The PCR conditions used for Tp9 were as described for
Tp1 and Tp2 (Pelle et al., 2011), except that annealing was per-
formed at 55 C for 1 min and the extension at 72 C was for
90 s. The amplicons were processed and sequenced either directly
or after cloning into a pGEM-T Easy plasmid vector (Promega) and
sequenced as previously described (Pelle et al., 2011).2.3.2. Processing of samples for high throughput sequencing
A multi-locus sequence typing system was established using
Roche (USA) 454 amplicon sequencing technology in order to iden-
tify allelic variants present at a low frequency in the vaccine stocks.
Primers were designed to amplify segments of 10 genes (292–
492 bp) known to encode antigens capable of recognition by
CD8+ T cells (Tp1–Tp10). Regions containing known CD8 T cell epi-
topes were selected. The primers were tested for their ability to
generate PCR products from a panel of 32 genotypically diverse
cloned T. parva-infected cell lines. These clones were derived by
limiting dilution from established T. parva-infected cell lines and
included genetically distinct clones of the Marikebuni stock pro-
duced by Katzer et al. (2006) (n = 10), and clones derived during
the course of the current study from isolates from cattle grazed
in proximity of buffalo (n = 8) (Bishop et al., 2015) and isolates
obtained from buffalo (n = 14) (Conrad et al., 1987). Specificity
was tested using DNA from other Theileria spp., T. annulata, Theile-
ria buffeli, Theileria taurotragi and Theileria sp. (buffalo), uninfected
bovine peripheral blood mononuclear cells (PBMC) and uninfected
R. appendiculatus ticks. Several primer combinations were tested
and for nine genes, primer pairs were identified that gave a product
of the expected size from each parasite clone which was specific
for T. parva (see Table 1). In order to take account of genetic poly-
morphism at the locus encoding Tp2, two pairs of primers were
designed to ensure amplification of all alleles. The same nucleotide
positions were targeted by each primer pair in separate reactions
and equal quantities of the two products were pooled prior to
sequencing. A longer amplicon (562 bp) was obtained for Tp2 than
for the other genes. Efforts to identify primers that would generate
a suitably sized PCR product for Tp9 from all parasite clones were
unsuccessful and therefore this gene was not pursued further.
Each primer was then modified to produce a fusion primer com-
prising three components, an adaptor sequence required for pro-
cessing of the amplicon for sequencing, a 10 nucleotide sequence
known as the Multiplex Identifier (MID) and the gene-specific pri-
mer sequence. The sequences of the adaptors and MIDs used were
those described in the Roche Technical bulletin (http://
454.com/downloads/my454). These fusion primers were then re-
tested to confirm they yielded PCR products of the expected size.
Amplicons were generated for the nine genes (Tp1–Tp8 and
Tp10) using the fusion primers in combination with a polymerase
with proofreading capacity. The primer concentrations and anneal-
ing temperatures used in each of the PCR assays are shown in
Table 1. For Tp1, Tp3, Tp4, Tp5, Tp6, Tp7 and Tp8, the reactions
comprised 5 ll of 10 Fast start High Fidelity reaction buffer con-
taining 18 mM MgCl2 (Roche) and 2.5 units of Fast start high fide-
lity enzyme blend (Roche), 1 ll of DNA and nuclease-free water in
a final volume of 50 ll. The cycling conditions were as follows:
95 C for 3 min followed by 30 cycles for 30 s at 95 C, 30 s at the
temperatures specified in Table 1 and 30 s at 72 C, followed by a
final extension at 72 C for 7 min. The melting temperature for
the primers designed for the amplification of Tp2 and Tp10 was
outside the working range of the Fast start high fidelity enzyme
blend (49 C). Therefore products for these genes were obtained
with a mixture of 1:1 Taq polymerase (Bioline, UK) and Pfu DNA
polymerase (Promega, UK). The PCR comprised 10–20 pmol of each
primer (see Table 1), 5 ll of custom PCR mix (Bioline), 1 ll of DNA
and nuclease-free water in a final volume of 50 ll. The cycling con-
ditions were as follows: 95 C for 3 min followed by 35 cycles of
95 C for 1 min, 49 C for 1 min and 72 C for 2 min, followed by
a final extension at 72 C for 7 min. PCR products were visualised
under UV light in 1.5% agarose gels containing SafeView nucleic
acid stain (NBS, Biologicals Ltd, UK) and bands corresponding to
the product of interest were excised. The PCR products were then
purified using the Promega Wizard Gel and PCR Clean-up System
(Promega Corporation, USA). The purity of PCR products was
Table 1
Sequences of Theileria parva gene primers incorporated into fusion primers, primer concentrations and annealing temperatures used to generate PCR amplicons from antigen
genes for high throughput sequencing.
Gene Primer sequences (50–30) Concentration (pmol/reaction) Annealing temp. (C) Amplicon sizea
Tp1 for-CTGGTGTACAATTTGGTGGG 20 55 428
rev-AACTTNMCTTCTTGCGAACC 20
Tp2 for-ATGAAATTGGCCGCCAGATTA 10 49 492
for-GCCAGATTAATHAGYCTTTAC 10
rev-AGATTTGTCACTAYCTGTWBYAGG 25
rev-AGATTCGTCCTCAYCTGTWBYAGG 25
Tp3 for-AGCAGATTTCACTCAAGCTGC 20 54 407
rev-TCCCCCAGAACATTAAACGG 20
Tp4 for-GCAACACAATACTTTGCAGG 10 54 424
rev-CCTCAAACACWCCACAAGTTCC 10
Tp5 for-GTATGCTCGGTAATGGCAG 10 55 347
rev-GATTTTGGTCGCTTCAGGC 10
Tp6 for-CGTCCAATAATTTACGATGTGAG 10
rev-GCTTAAGTGGGTTAAGGAGACA 10 55 326
Tp7 for-TGAAGAAGGACGACTCGCAC 20 58 292
rev-TCCTCGTCAGTGACGTCGG 20
Tp8 for-ATCCACAACCAAGTGCCCAG 10 54 305
rev-TGCTATTGCGAGTCAACAG 10
Tp10 for-GGTCGTCTGACAATAACC 10 49 314
rev-CTAMCATGTAAATCCAGC 20
a The expected amplicon sizes (excluding the adaptor and Multiplex Identifier (MID) sequence of the fusion primer), based on the Muguga reference genome sequence.
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(Agilent Technologies, USA). PCR products were quantified using
a picogreen assay (Thermo Fischer Scientific, USA). Equimolar
quantities of PCR products were pooled and submitted to the
Centre for Genomics Research (CGR), University of Liverpool, UK
for Roche 454 sequencing.
2.4. Analysis of high throughput sequence data
Raw 454 sequencing data were processed using a custom bioin-
formatics pipeline. Briefly, reads for individual PCRs were extracted
from multiplexed sequence datasets on the basis of the MID tags
and primer sequences present within each read. As sequence qual-
ity was reduced towards the end of the relatively long Tp2 reads,
and forward and reverse reads could not be paired with confidence,
only the first 290 bases of the forward reads were analysed for this
gene. The raw reads for a single gene in a single sample were then
subjected to noise reduction (shhh.flows and shhh.seqs) and chi-
maera detection algorithms implemented on the Mothur platform
(Schloss et al., 2009). Three different algorithms were used in order
to maximise the chance of chimaera detection, namely Perseus,
Chimera slayer and Uchime (Edgar et al., 2011; Haas et al., 2011;
Quince et al., 2011). ‘Variants’ at a frequency below 0.4% or below
five reads were removed from the dataset. These cut-offs were cho-
sen based on control experiments where sequences were obtained
from every gene following amplification from a clonal parasite
stock. Resulting sequences were aligned using MUSCLE (Edgar,
2004) and visualised using the MEGA 5 phylogenetics suite
(Tamura et al., 2011). Due to the presence of homopolymeric-
length errors, which are intrinsic to 454 technology, single nucleo-
tides were added to or deleted from sequence reads as necessary
when the length of a homopolymer tract differed from that of
the most abundant allele(s); not correcting such errors would have
led to frame shifts and thus a change to the translated sequence
and/or premature stop codons. Where single base pair insertions
and deletions altered the reading frame of the gene, these were
assumed to be artefacts and the reads discarded.
The aim was to obtain a minimum of 1,200 reads per gene per
sample, equating to a 99.3% chance of detecting five or more reads
representing an allele present at a frequency of 1%. In some cases,this required data from different sequencing runs to be combined
in order to obtain sufficient depth. With the exception of the Tp2
gene, the target of obtaining 1,200 usable reads per gene was
exceeded for all genes in each of the Muguga cocktail components;
the Tp2 gene yielded approximately 500 reads for each component.3. Results
3.1. Micro- and mini-satellite genotyping of the Muguga cocktail
stocks
Genotypic diversity within the T. parva stocks used in the
Muguga cocktail was first assessed using a panel of 15 micro-
and mini-satellite markers distributed across the four parasite
chromosomes. The use of capillary electrophoresis to detect
micro- and mini-satellite alleles also allowed estimation of the rel-
ative proportions of genotypes present in each parasite sample.
The alleles detected and their relative representation within the
three parasite stocks are shown in Fig. 1 and the overall diversity
of alleles in the Muguga cocktail is summarised in Table 2. Overall,
each of the stocks showed limited intra-stock diversity. Only a sin-
gle allele was detected for 14 of the 15 loci examined in the
Kiambu 5 stock; two alleles were found for the remaining locus.
Similarly, a single allele was detected with 11 of the satellite mark-
ers in the Muguga stock and with eight of the satellite markers in
the Serengeti stock. The remaining four satellite markers in the
Muguga stock and five of the remaining markers in Serengeti
detected a single additional allele, while two additional alleles of
MS8 andMS25 were detected in the Serengeti stock. The genotypes
of Muguga and Serengeti stocks exhibited a high level of similarity,
with at least one allele shared between the stocks for each of the
markers. By contrast, the predominant allele detected with 10 of
the 15 satellite markers in the Kiambu 5 stock was either unique
to this stock (three markers) or present as a minor component
(<20%) in either or both of the other stocks. PCoA based on the level
of genetic differentiation between each stock illustrates a high
level of similarity between the Muguga (Stabilate 4230) and
Serengeti (Stabilate 4229) stocks and the distinct profile for the
Kiambu 5 stock (Fig. 2).
Table 2
Summary of numbers and alleles and their lengths (bp) detected in the Muguga cocktail Theileria parva vaccine by typing with 15 mini- and
microsatellite markers.
Allele sizes (bp) detected for each satellite marker
Chromosome 1 Chromosome 2 Chromosome 3 Chromosome 4
ms2 MS3 MS7 MS8 ms7 MS14 MS15 MS19 MS21 MS25 MS27 MS30 MS33 MS39 MS40
359a 258 309 311 170 340 204 295 325 324 209 213 214 263 188
113 307 289 331 145 116 304 245 309 149 189 214
372 263 321 255
321
aThose listed in the first horizontal row are the alleles represented by black fill in Figs. 1 and 3. The alleles in the reference genome are
indicated by grey shading.
Fig. 1. Illustration of the numbers and relative frequencies of micro- and mini-satellite alleles detected in the three components of the Muguga cocktail vaccine (Muguga,
Serengeti and Kiambu 5). Alleles are denoted by different fill patterns, the black shaded allele representing the most abundant allele in the Muguga isolate.
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Fig. 2. Results of principal co-ordinate analysis of satellite typing data obtained for
the individual components of the Muguga cocktail vaccine (Muguga, Serengeti and
Kiambu 5) and the four batches of the Muguga cocktail vaccine (ILRI 0801–0804).
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on four batches of the Muguga cocktail vaccine (ILRI 0801–0804)
to determine whether the composition of the parasite cocktail
reflected that of the individual components described above
(Muguga, Serengeti and Kiambu 5). The results are presented in
Fig. 3. All alleles found in the individual components were present
in the vaccine batches, with the exception of a minor allele of MS8,
which was below the threshold value for acceptance. Similarly, all
alleles identified in each of the vaccine batches could be identified
in one or more component stocks. In addition, there was a high
level of consistency between batches, both in terms of the alleles
detected and their relative abundance. PCoA revealed a close
similarity between the four Muguga cocktail batches, illustrated
in Fig. 2 as a tight cluster with little differentiation between
batches (FST = 0.003 ± 0.001). Given that the Muguga and Serengeti
components were highly similar to one another and that they
constitute two-thirds of the vaccine cocktail, it was anticipated
that the vaccine batches would be more similar to these
components than the Kiambu 5 component and this was confirmed
by the PCoA analysis.
3.2. Antigen gene sequence diversity in the Muguga cocktail
component stocks
Genotypic diversity within and among the T. parva stocks that
constitute the Muguga cocktail was further investigated by
multi-locus sequencing of genes encoding CD8+ T cell antigens by
applying high throughput sequencing using Roche 454 technology.
The number of alleles detected for each gene and their relative pro-
portions in each stock are illustrated in Fig. 4. Details of the alleles
identified among component stocks of the Muguga cocktail are
summarised in Table 3. With the exception of a single di-
nucleotide deletion within an intron region of one Tp10 allele, all
allelic differences were due to point mutations.
Despite the considerable sequencing depth achieved, the num-
ber of allelic variants identified in each of the component stocks
was low (one to four alleles). With the exception of one gene in
Kiambu 5 (Tp3), a single dominant allele accounted for more than
90% of the reads obtained for each gene in each of the three stocks.
Moreover, the alleles detected within each stock and in the differ-
ent stocks showed a high level of sequence identity (>95%), with
the majority of the nucleotide differences not resulting in amino
acid polymorphism (Table 3). Amino acid residue polymorphism
was found only among alleles of Tp2, Tp3, Tp7 and Tp10.
In the Muguga stock, only a single allele was detected for each
gene except Tp6, which had a second allele present at low abun-
dance (0.77%), containing four synonymous substitutions in the
291 nucleotide sequence with respect to the major allele. Acrossthe loci, the same predominant alleles found in the Muguga stock
also dominated the Serengeti stock, accounting for all of the
sequence reads obtained for five of the genes and more than 90%
of reads for the remaining four genes (Tp2, Tp5, Tp6 and Tp10).
An additional allele was detected for the latter four genes, which
differed from the reference Muguga allele by between two and
10 nucleotide positions. With the exception of the two mutations
in Tp2 (see Table 3), these differences did not result in an alteration
to the predicted amino acid sequence. A single allele was detected
for six of the genes in the Kiambu 5 stock, two of which (Tp1 and
Tp8) were identical to that found in the Muguga stock and four
(Tp2, Tp5, Tp6 and Tp10) were identical to the minor alleles found
in the Serengeti stock. The remaining three genes, Tp3, Tp4 and
Tp7, shared one allele with Muguga or Serengeti stock, but also
had between one and three additional alleles. The two additional
alleles for Tp3 had residue changes over nine and 10 nucleotide
positions compared with the Muguga allele, leading to three and
four amino acid changes, respectively. The three variant Tp4 alleles
had between 21 and 31 nucleotide substitutions compared with
the Muguga allele, but all were within an intron and hence did
not alter the coding sequence. The Tp7 variant allele contained
seven nucleotide substitutions over the length of the amplicon
(253 bp), leading to only one amino acid change.
3.3. Antigenic diversity in the Muguga cocktail component stocks
Previous studies have identified CD8 epitopes in six of the nine
antigen genes examined (Graham et al., 2008) and a single epitope
in Tp10 is reported in the present study. Alleles containing amino
acid coding changes were only detected in two of these genes. The
single amino acid substitution found in Tp7 lies outside the
epitope-encoding region. However, the two amino acid changes
in Tp2 both lie within one of the defined epitopes (Tp227–37) and
result in substitutions at positions 2 (H?D) and 6 (K?N) of the
epitope (Table 4).
3.4. Analyses of Tp9 sequence diversity by Sanger sequencing
3.4.1. Demonstration of sequence polymorphism in the Tp9 gene
The initial failure to design primers that could reproducibly
generate PCR products suitable for 454 sequencing from the Tp9
gene suggested that this gene is polymorphic. Sanger sequencing
was therefore conducted on full-length PCR products from cloned
sporozoite stabilates of five cattle-derived T. parva isolates –
Muguga, Boleni, Uganda, Mariakani and Marikebuni (Morzaria
et al., 1995). The Tp9 sequences obtained from the cloned Muguga
and Uganda parasites were identical to the 1,005 bp reference
Muguga gene, but each of the other clones contained a different
allele (GenBank IDs: JN828541, JN828544, JN828549, JN828552).
The Boleni sequence was similar to the Muguga reference, differing
only by the presence of a 30 nucleotide insert in the central region
of the gene. The Mariakani and Marikebuni Tp9 sequences were
highly divergent from the reference due to numerous amino acid
substitutions as well as several insertions and deletions. The latter
resulted in differences in the length of the coding region (957 bp
for Mariakani and 1,107 bp for Marikebuni). Translation of these
sequences confirmed four alleles of the Tp9 protein (Supplemen-
tary Fig. S1). The CD8+ T cell epitope identified in Tp9 exhibited
amino acid substitutions in six of the nine amino acids in both
the Marikebuni and Mariakani sequences, which differed from
each other at two residues.
3.4.2. Analysis of Tp9 in the Muguga cocktail components
PCR amplicons of Tp9 obtained from a series of cloned T. parva-
infected cell lines derived from each of the three Muguga cocktail
stocks were subjected to Sanger sequencing. These cloned lines
Fig. 3. Illustration of the number and relative frequencies of micro- and mini-satellite alleles detected in four batches of the Muguga cocktail vaccine (ILRI 0801–ILRI 0804,
labelled 1–4). Alleles are denoted by different fill patterns, employing the same key used in Fig. 1.
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Serengeti and 11 with Kiambu 5. Sequences were also determined
for Tp1 and Tp2. The findings for both of these genes were
consistent with the results of the 454 sequencing, in that only
one variant sequence of Tp2, present in all of the Kiambu clones
and in all except two of the 10 Serengeti clones, was found. In the
case of Tp9, all of the sequences of theMuguga and Serengeti clones
were identical to the genome reference sequence, whereas all 11
clones of Kiambu 5 had a distinct allele (Supplementary Fig. S1),
which was very similar to that described above for the Mariakani
isolate, differing only at five nucleotide positions and encoding an
additional amino acid residue within the first 17 nucleotides.3.5. Antigen gene sequence diversity in the Marikebuni stock
Multi-locus 454 sequencing of the same set of nine genes was
performed on the Marikebuni stock of T. parva. The results are
illustrated in Fig. 4 and summarised in Table 5. Single alleles,
which were identical to the Muguga genome reference sequence,
were detected for four of the genes (Tp3, Tp4, Tp6 and Tp8). Two
alleles were identified for three genes (Tp1, Tp5, and Tp7) and four
alleles for the remaining two genes (Tp2 and Tp10). Six of these
alleles (one for Tp1, two for Tp2, one for Tp7 and two for Tp10)
were distinct from those found in the Muguga cocktail. In all cases,
a single allele accounted for more than 90% of the sequence reads.
Fig. 4. Illustration of the numbers and relative frequencies of antigen gene alleles found using high throughput multi-locus sequencing of genes encoding CD8 antigens in the
three components of the Muguga cocktail vaccine (Muguga, Serengeti and Kiambu 5) and the Marikebuni stock. Alleles are denoted by different fill patterns, the black shaded
allele representing the most abundant allele in the Muguga isolate. The results for Tp2 (Tp2F) are based on forward sequence reads only. The National Center for
Biotechnology Information (NCBI, USA) sequence read archive (SRA) accession number for these sequence data is SRP065583.
Table 3
Numbers of Theileria parva antigen gene sequence alleles and total number of polymorphic residues present in allelic variants detected in the components of the Muguga cocktail
vaccine (Kiambu 5, Serengeti and Muguga).
Gene Total number of sequence readsa Polymorphic nucleotides No. alleles (nucleotide level) Polymorphic amino acids No. alleles (amino acid level)
Tp1 6,156 0/393 1 0/131 1
Tp2 1,596 2/290 2 2/96 2
Tp3b 7,196 16/366 3 7/110 3
Tp4b 4,314 41/382 4 0/40 1
Tp5b 16,214 4/308 2 0/62 1
Tp6 4,263 10/291 3 0/96 1
Tp7 13,356 7/253 2 1/84 2
Tp8 11,364 0/262 1 0/87 1
Tp10b 12,360 3/277 2 1/59 2
a The total of sequence reads for the Muguga cocktail is the sum of reads obtained for each of the individual stocks.
b These genes contain introns, accounting for the discrepancies between nucleotide and amino acid lengths.
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between alleles was very low. The sequence polymorphism
resulted in amino acid substitutions in defined CD8+ T cell epitopes
in only two of the antigens (Table 5). A single allelic variant was
found for the Tp1214-224 epitope and two allelic variants were
detected for all three Tp2 epitopes represented in the
partial sequence reads obtained for this gene (Tp227–37, Tp240–48,Tp249–59). The epitope variants differed by between one and six
amino acid residues from the reference sequence (Table 4).
Sanger sequencing of 17 clones of the partial Tp9 DNA ampli-
fied by PCR from the Marikebuni stock revealed four alleles,
including one identical to the Muguga reference sequence (11
clones). A further allele differed by only two nucleotides from
the reference sequence (two clones), leading to one amino acid
Table 4
Amino acid sequences of variant CD8 T cell epitopesa detected within the Muguga cocktail and the Marikebuli stock of
Theileria parva.
Origin of parasite 
material
Tp1 antigen Tp2 antigen
Tp1214-224 Tp227-37 Tp240-48 Tp249-59
Muguga cocktail VGYPKVKEEML SHEELKKLGML DGFDRDALF KSSHGMGKVGK
SDEELNKLGML
Marikebuni stock VGYPKVKEEML
VGYPKVKEEII
SHEELKKLGML
SDEELETLGML
SEAELRKMGMI
DGFDRDALF
PNPDKEKLF
GNFDRELLF
KSSHGMGKVGK
KSSHGMGKIGK
LTSKAMMTVGK
aResidues showing amino acid substitutions compared with the reference sequence are bold and highlighted in grey.
Table 5
Numbers of Theileria parva antigen gene sequence alleles and total number of polymorphic residues present in allelic variants detected in the Marikebuni stock.
Gene Total number of sequence reads Polymorphic nucleotides No. alleles (nucleotide level) Polymorphic amino acids No. alleles (amino acid level)
Tp1 290 4/393 2 2/131 2
Tp2 1,484 107/290 3 53/96 3
Tp3a 352 0/366 1 0/110 1
Tp4a 530 0/382 1 0/40 1
Tp5a 4,771 4/308 2 0/62 1
Tp6 1,933 0/291 1 0/96 1
Tp7 1,875 3/253 2 0/84 1
Tp8 15,445 0/262 1 0/87 1
Tp10a 12,267 3/277 4 1/59 2
a These genes contain introns, accounting for the discrepancies between nucleotide and amino acid lengths.
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clones each) (only differing at one nucleotide position, leading
to an amino acid change), but differed from the Muguga allele
at 44 nucleotide residues, leading to 28 amino acid substitutions,
and had a 9 bp deletion.
3.6. Comparison of diversity with that of field populations of T. parva
Previous studies of the sequences of the Tp1 and Tp2 genes in
field populations of T. parva have shown that both genes exhibit
extensive allelic diversity, which was particularly marked in
buffalo-derived parasite isolates (Pelle et al., 2011). Herein, we
have also detected four alleles of the Tp9 gene in a small sample
of cattle-derived parasite isolates. A comparison of these findings,
with sequence data obtained for Tp1, Tp2 and Tp9 from the
Muguga cocktail and the Marikebuni stock, is presented in Table 6.
In contrast to the large number (more than 25) of amino acid
sequence variants of Tp1 and Tp2 detected by Pelle et al. (2011)
in 82 field isolates of T. parva, the Muguga cocktail contained no
Tp1 variants and only a single variant allele of Tp2 in addition to
the reference Muguga alleles of the two genes. Moreover, the Tp2Table 6
Comparison of the number of alleles detected for the Tp1, Tp2 and Tp9 gene sequences in
alleles detected previously in field isolates of Theileria parva.
Source of parasite material Number of isolates Tp1 alleles
DNA Ami
Vaccine stocks
Muguga cocktail 3 1 1
Marikebuni 1 2 2
Field isolatesa
Cattle 41 12 10
Buffalo 41 26 26
nt, not tested.
a Numbers of alleles detected by sequencing Tp1 and Tp2 genes in 82 field isolates ovariant was antigenically similar to the reference sequence,
differing at only one of the six defined CD8+ T cell epitopes
identified in this antigen. The more limited sequence data obtained
for Tp9 revealed only one amino acid variant, in addition to the
genome reference sequence, within the Muguga cocktail. Hence,
with respect to these antigens, the Muguga cocktail incorporates
very little of the observed diversity in field populations of T. parva.
The results obtained for the Marikebuni stock revealed one, two
and three sequence variants of Tp1, Tp2 and Tp9, respectively, in
addition to the genome reference sequence. These included alleles
that showed extensive divergence in the encoded amino acid
sequence including the CD8+ T cell epitopes. Hence, the Marikebuni
stock contains greater diversity in these antigens than the Muguga
cocktail.4. Discussion
The aim of this study was to use multi-locus sequencing of
genes encoding currently identified CD8+ T cell antigens in combi-
nation with micro- and mini-satellite genotyping, to determine thethe Muguga cocktail vaccine stabilates and the Marikebuni stock, with the number of
Tp2 alleles Tp9 alleles
no acid DNA Amino acid DNA Amino acid
2 2 2 2
3 3 4 4
5 4 nt nt
38 38 nt nt
f T. parva reported by Pelle et al. (2011).
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Muguga cocktail live T. parva vaccine. The results indicate that,
overall, the Muguga cocktail vaccine incorporates very little of
the genetic and antigenic diversity observed in field populations
of T. parva.
Roche 454 sequencing of PCR amplicons of antigen-encoding
genes was utilised in order to provide greater resolution than
had been achieved in previous studies. Preliminary experiments
indicated reliable detection of sequence variants present at 0.4%
using this method. Use of capillary electrophoresis to detect
micro- and mini-satellite alleles also allowed estimation of the rel-
ative proportions of genotypes present in each parasite sample. In
agreement with previous micro- and mini-satellite genotyping
results obtained by Oura et al. (2004), a limited amount of diversity
was observed within the components of the Muguga cocktail.
Despite the higher resolution afforded by high-throughput
sequencing with respect to the detection of rare alleles, this
method also revealed limited but appreciable diversity within
the vaccine components. A major contributory factor to the overall
limited diversity within the Muguga cocktail as a whole was the
large number of loci where the Muguga and Serengeti components
shared either a single or a clearly predominant allele. This similar-
ity is re-inforced by the whole-genome sequencing effort recently
applied to the vaccine component stocks using a gene capture
method (Norling et al., 2015), which did not provide evidence of
intra-component diversity. However, interestingly, in that study
no bi-allelic single nucleotide polymorphisms (SNPs) were identi-
fied within the Serengeti transformed stock (which we found to
be relatively homogeneous) while 18 SNPs were identified within
Kiambu 5. While the number of putative SNPs was noted to be
within the error rate of the sequencing platform used in that study
and the component stock assumed to be clonal, the present tar-
geted amplicon sequencing approach clearly demonstrates that
Kiambu 5 is heterogeneous with, for example, the Tp3 locus dis-
playing three alleles and an estimated heterozygosity of approxi-
mately 53% (Fig. 4). The discrepancy is almost certainly due to
the greater ability of the methods used in the current study to
detect alleles present at low frequency.
In view of the diverse origins of the parasite stocks, it is surpris-
ing to find such a high degree of similarity between the Serengeti
and Muguga parasites. The Serengeti stock was originally isolated
from buffalo (Young and Purnell, 1973), in which the T. parva pop-
ulation is known to possess enormous genotypic diversity (Oura
et al., 2011; Pelle et al., 2011). Although buffalo T. parva parasites
readily infect cattle and cause severe disease, they usually differen-
tiate poorly to the tick-infective intra-erythrocytic stage and there-
fore onward transmission via the tick either does not occur or does
so with very low efficiency (Barnett and Brocklesby, 1966; Mbizeni
et al., 2013). The limited diversity in the Serengeti stock could be
explained by a bottleneck in the cattle-tick cycle, in which only a
small subset of the parasites in the original Serengeti could adapt
to continued passage through cattle and ticks. However, the likeli-
hood that the selected parasite would be highly similar to the
Muguga isolate seems remote and therefore these findings raise
the possibility that the Serengeti stock has become contaminated
with parasites from the Muguga stock at some time following its
isolation from the field. This has also been suggested recently by
Norling et al. (2015), based on genome sequence data.
The parasite stocks currently used for the production of the
Muguga cocktail have undergone several cattle-tick-cattle pas-
sages since the formulation of the Muguga cocktail in the 1970s
and, at least for the Serengeti stock, it appears very likely the com-
position of the stock has changed since its isolation. Micro- and
mini-satellite DNA typing and high-throughput multi-locus
sequence typing reveal the presence of alleles at a low frequency
in the vaccine and each of its component parts. As each componenthas been maintained in isolation, it is logical to view each as a sub-
population of T. parva genotypes. Field studies of T. parva have pre-
viously documented appreciable polymorphism at a number of the
antigen (Pelle et al., 2011) and satellite marker loci (Oura et al.,
2005, 2011) used in this study. Moreover, mixed genotypes were
frequently detected in single samples from naturally infected ani-
mals (Oura et al., 2005). It is interesting to note that within each of
the three individual vaccine component stocks, the majority of loci
display no polymorphism while others show two to four alleles. In
broad terms, therefore, the genotypes within a component can be
said to share a remarkably high degree of similarity. This lies in
contrast to the low level of similarity which two unrelated field
isolates would be expected to share. It can therefore be surmised
that each component stock represents a highly inbred parasite
population. As each stock has undergone extensive cattle-tick-
cattle passage in isolation, it is likely that the present day stocks
represent an inbred population derived from the original field iso-
lates. Each component is genetically isolated and will have a small
effective population size. The parasite may, therefore, be subjected
to significant bottlenecking through stochastic processes related to
the limited number of cattle/ticks used to maintain the population
coupled with the potential for selection of particular genotypes in
the cattle host. Consequently, it may be hypothesised that two evo-
lutionary ‘drivers’ will act to reduce the diversity at each locus –
selection and genetic drift.
Mathematical modelling of field data suggests that a large pro-
portion of tick transmissions of T. parva are from carrier cattle, i.e.
animals with persistent infection following resolution of the acute
phase of infection (Medley et al., 1993). There is also evidence that
carrier cattle can acquire infection with additional parasite geno-
types following tick challenge, thus resulting in carriage of mixed
genotypes (Oura et al., 2007), which have the potential to recom-
bine during subsequent transmission by ticks. The selective pres-
sures in the field, where carrier infections play a prominent role
in transmission, are likely to be different than those experienced
by laboratory stocks, which are maintained in isolation by repeated
tick passage from acutely infected cattle. Hence, it seems likely
that different parasite genotypes will have differing levels of fit-
ness in the course of this regime of passage through the parasite
life-cycle. Consequently, genotypes with loci conferring a long-
term passage ‘fitness’ would be positively selected in each compo-
nent population and genetically linked regions surrounding such
loci would also be selected by way of a genetic hitch-hiking effect.
In addition to any selective pressure, given that the parasite popu-
lation is relatively small and isolated, it is likely that genetic drift
will result in alleles being lost from each component population
in a stochastic manner during the course of successive passages.
It has been demonstrated previously that changes to the parasite
population can occur with additional cattle-tick passages for the
Marikebuni stock, a stock that has also been used for immunisation
in the field (Katzer et al., 2006). The current study demonstrated
that an early passage of the Marikebuni stock (stabilate 3014) con-
tained relatively greater diversity than any of the Muguga cocktail
components. However, by applying micro- and mini-satellite geno-
typing to sequential passages of this stock, Katzer et al. (2006)
identified changes in allele frequencies at each passage. This
resulted in a stock that was quite distinct from the original after
only three rounds of passage, with a minor component becoming
dominant in the latter. It is of note that the Muguga stock, which
has very limited diversity, has been subjected to prolonged pas-
sage, having been maintained by regular tick passage following
its isolation in 1961 until the early 1970s when procedures for cry-
opreservation were developed (Cunningham et al., 1973). Unfortu-
nately, without archive material with which to determine the early
composition of the component stocks of the Muguga cocktail, it is
impossible to estimate the scale of loss of genetic diversity through
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clear and present threat to the stability of each of the vaccine com-
ponents as they are maintained by cattle-tick passage, with low
frequency alleles being at greatest risk. Although the present study
demonstrates that four batches of vaccine prepared at different
time points from the same batches of infected ticks show very sim-
ilar composition of parasite genotypes, it is unknown how this con-
sistency is maintained when vaccine batches are produced using
stabilates that have undergone additional cattle-tick passage.
Another concern is whether the genetic diversity within each com-
ponent will be present within every dose of the Muguga cocktail
vaccine. One of the goals of early studies with cryopreserved T.
parva sporozoites was to establish a dose of parasites that would
result in mild clinical reaction with recovery in all animals, which
could be used for vaccination. However, titrated doses of sporo-
zoites resulted in variable reactions; at doses that did not give sev-
ere reactions in any animals, some of the animals did not become
infected, as judged by the absence of detectable parasites and sus-
ceptibility to subsequent parasite challenge (Cunningham et al.,
1974). Moreover, there was a relatively narrow dose range (100
fold) between most animals developing severe reactions and some
animals not becoming infected, suggesting that a few thousand or
fewer infection events in vivo are sufficient to result in severe dis-
ease. Hence, at the doses used for infection and treatment, it is
uncertain whether low frequency parasite genotypes will be pre-
sent in every vaccine dose and whether they make a meaningful
contribution to the breadth of immunity induced by vaccination.
Despite the concerns regarding parasite composition, vaccina-
tion of cattle with the Muguga cocktail appears to be effective in
the field (Di Giulio et al., 2008). The obvious question arising from
the results of the current study is why, given its limited diversity, is
it able to provide broad protection? Our current knowledge of the
immunological basis of strain specificity of immunity following
immunisation with individual parasite isolates indicates that it is
a consequence of strong immunodominance hierarchies in the
antigens recognised by the specific CD8+ T cell response, resulting
in the response in each animal being focused on a few antigens, the
most dominant of which tend to be polymorphic in the parasite
population (reviewed in Morrison et al., 2015). The antigen domi-
nance hierarchy varies between animals of different MHC geno-
types and can be influenced by the parasite isolate used for
immunisation (Taracha et al., 1995b). The latter, in part, reflects
the capacity of the parasite to undergo frequent sexual recombina-
tion during transmission of heterogeneous parasite populations
(Oura et al., 2005; Katzer et al., 2011), such that allelic variants
of different antigens can occur in different combinations in differ-
ent parasite genotypes. The specificity of responses induced by
immunisation with mixtures of parasite isolates has not been
investigated. However, since the antigens expressed by each
constituent parasite genotype will infect different cells and present
a different but overlapping repertoire of antigens to responding
T cells, each parasite might be expected to generate its own CD8+
T cell response against different dominant antigens. Consequently,
the overall CD8+ T cell response is likely to comprise a wider range
of antigenic specificities than that induced by the individual para-
sites, increasing the likelihood that one or more of the specificities
will recognise parasite genotypes encountered upon field chal-
lenge. In this model (elaborated further in Morrison et al., 2015),
the immunising parasites do not necessarily need to include all
of alleles of each polymorphic antigen to generate broad protec-
tion. If this model is correct, the precise parasite populations used
within a live cocktail vaccine may not be critical, providing they
are relatively antigenically diverse. To what extent this scenario
applies to other protozoal pathogens remains unclear. Among
those referred to earlier, immunity to Eimeria spp. is mediated pre-
dominantly by T cell responses (Smith and Hayday, 2000) and datafrom cross-immunity studies indicate that a similar immunodom-
inance phenomenon may account for the lack of cross-protection
between of isolates of Eimeria maxima (Smith et al., 2002).
On the basis of the model proposed above and given the results
of the current study, we propose that an improved T. parva cocktail
could be produced using a mixture of genotypically diverse cloned
parasites. Given that the Muguga cocktail essentially consists of
two major components, we hypothesise that three genotypically
distinct clones would be sufficient to induce a similar or greater
breadth of protection than the Muguga cocktail. Methods for
obtaining sporozoite preparations from cloned parasites are well
established (Morzaria et al., 1995) and genome sequencing could
be employed to aid selection of the most genotypically and
antigenically diverse clones. Field trials would be required to test
the efficacy of such a vaccine. The use of cloned parasites would
eliminate the concerns associated with the loss of minor genotypic
components from uncloned parasite populations and enable
the parasite composition of the vaccine to be measured with
greater precision, thereby improving the quality control of
vaccine batches.
However, until a more standardised vaccine is formulated, it
remains essential to monitor the composition of different batches
of the current vaccine, especially if the stocks used for vaccine pro-
duction have been subjected to additional passages through cattle
and ticks. The results of the current study provide useful reference
data on which to establish molecular typing methods for monitor-
ing the composition of the vaccine.
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